Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point
Authors
Keywords
-
Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 75, Issue 8, Pages 1479-1485
Publisher
BMJ
Online
2015-09-30
DOI
10.1136/annrheumdis-2015-208324
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
- (2015) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
- (2014) Roy Fleischmann et al. ANNALS OF THE RHEUMATIC DISEASES
- Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies
- (2014) Tsutomu Takeuchi et al. Modern Rheumatology
- Proposal for a new nomenclature of disease-modifying antirheumatic drugs: Table 1
- (2013) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index
- (2012) Daniel Aletaha et al. ANNALS OF THE RHEUMATIC DISEASES
- Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients
- (2012) Daniel Aletaha et al. ANNALS OF THE RHEUMATIC DISEASES
- Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions
- (2012) Paul Studenic et al. ANNALS OF THE RHEUMATIC DISEASES
- Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial
- (2012) DÉSIRÉE VAN DER HEIJDE et al. JOURNAL OF RHEUMATOLOGY
- Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction
- (2011) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials
- (2011) David T. Felson et al. ARTHRITIS AND RHEUMATISM
- Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: Experience from a large US cohort
- (2011) Jie Zhang et al. ARTHRITIS CARE & RESEARCH
- Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice
- (2011) Grant W. Cannon et al. ARTHRITIS CARE & RESEARCH
- Treating rheumatoid arthritis to target: recommendations of an international task force
- (2010) J. S. Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
- (2010) P. P. Tak et al. ANNALS OF THE RHEUMATIC DISEASES
- Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baseline
- (2009) D. Aletaha et al. ARTHRITIS AND RHEUMATISM
- Golimumab, a human antibody to tumour necrosis factor given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
- (2008) E C Keystone et al. ANNALS OF THE RHEUMATIC DISEASES
- The importance of reporting disease activity states in rheumatoid arthritis clinical trials
- (2008) Daniel Aletaha et al. ARTHRITIS AND RHEUMATISM
- Activity assessments in rheumatoid arthritis
- (2008) Josef S Smolen et al. CURRENT OPINION IN RHEUMATOLOGY
- The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?
- (2008) Josef S Smolen et al. ARTHRITIS RESEARCH & THERAPY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started